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Background: Heart failure (HF) is characterized by neurohormonal activation, adverse cardiac remodeling and inflammation. Statins have anti-
inflammatory actions, but data on their effects in HF has been conflicting.
Methods: We used the Multiplex assay (Luminex-100) ELISA system to measure plasma concentrations of a panel of cytokines, chemokines, matrix 
metalloproteinases (MMPs) and tissue inhibitors of MMP (TIMPs) from 26 patients with nonischemic, systolic HF randomized to atorvastatin (10 mg) 
or placebo for 3 months.
Results: There was a significant (p≤0.05) increase in the anti-inflammatory marker IL-10 as well as an increase in some pro-inflammatory markers, 
including TNF-_, IL-5, IL-7, IL-10, IL-12p70 and lymphotactin, in subjects randomized to atorvastatin (Table 1). A decrease in the concentration of 
pro-remodeling marker MMP-7 was noted in the atorvastatin group as well. There was no change in hsCRP, BNP, IL-1a, -1b, -2, -4, -6, -8, -13, -15, 
IFN-a, MMP-1, -2, -9, -10, TIMP-3, -4, TGF-`, EGF, FGF-2, GM-CSF, M-CSF, GCP-2, I-TAC, MIG, MCP-1 or MCP-3 in the atorvastatin group. There was also 
no change in any biomarker in the placebo group.
Conclusions: Short-term statin therapy in non-ischemic HF was associated with alterations of the inflammatory milieu. However, this response may 
not be robust or consistent enough to alter the course of HF, in light of the negative outcomes of major clinical trials of statins in HF. 
Table 1
Atorvastatin Group Placebo Group
Baseline Final P-Value Baseline Final P-Value
LDL-Cholesterol mg/dl 106.2 ± 23.0 66.5 ± 18.6 0.001 109.1 ± 29.0 111.3 ± 31.0 0.71
Total Cholesterol mg/dl 183.1 ± 35.1 137.7 ± 23.3 0.0001 188.2 ± 38.0 183.1 ± 43.7 0.881
IL-5 pg/ml 0.8 (0.3-2.8) 1.9 (0.6-3.3) 0.015 1.1 (0.4-2.1) 1.0 (0.7-2.4) 0.917
IL-7 pg/ml 3.1 (1.9-6.1) 5.5 (2.3-9.7) 0.023 3.6 (1.8-8.0) 3.7 (2.0-7.7) 0.807
IL-10 pg/ml 13.6 (9.8-40.2) 23.5 (19.9-43.2) 0.05 22.3 (11.9-42.5) 22.7 (12.3-34.7) 0.507
IL-12p70 pg/ml 4.5 (0.5-14.0) 10.2 (4.8-20.8) 0.038 4.3 (0.8-15.3) 3.4 (2.2-11.5) 0.507
TNF-_ pg/ml 4.2 (3.2-7.1) 7.1 (4.1-9.1) 0.045 6.0 (4.6-7.9) 4.7 (3.4-8.8) 0.345
Lymphotactin pg/ml 70.8 (59.0-92.0) 92.0 (70.8-124.5) 0.032 81.4 (64.9-105.2) 92.0 (70.8-120.0) 1.000
MMP-7 pg/ml 3752.3 (3101-6349) 3060.6 (1138-3946) 0.01 4364.6 (3532-6675) 4648.4 (2909-6716) 0.133
Mean ± Standard Deviation or Median (25th-75th percentile) 
